MHB042C

MHB042C is an investigational next‑generation antibody‑drug conjugate (ADC) targeting the hepatocyte growth factor receptor c‑Met, developed by Minghui Pharmaceutical for the treatment of advanced solid tumors.[3][5][12] It consists of a VHH‑Fc fusion protein directed against c‑Met conjugated to a proprietary, highly potent DNA topoisomerase I–inhibiting payload, designed to deliver selective cytotoxicity to c‑Met–expressing tumor cells while limiting off‑target toxicity.[3][5][12] Preclinical studies have shown potent antitumor activity in vitro and in vivo with a favorable safety profile, supporting advancement into a first‑in‑human, open‑label, multicenter phase I/II trial evaluating intravenous MHB042C monotherapy in patients with advanced malignant solid neoplasms.[1][3][5][6][7] The clinical program is focused on defining the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of MHB042C and establishing the recommended phase II dose for selected c‑Met–positive solid tumor indications.[5][6][7]